Senior management changes at Aastrom Biosciences
This article was originally published in Scrip
Executive Summary
Aastrom Biosciences (US) has announced that its CEO, president, chief financial officer and director, George Dunbar, will move out of day-to-day management duties and is expected to assume the role of chairman after the company's annual meeting of shareholders, which is planned for December 14th. Timothy Mayleben, a member of the company's board of directors and chair of the audit committee, will remain as a director and will become the Aastrom's new CEO, president and CFO in December. Nelson Sims, who has served as chairman since October 2008, is expected to assume the role of lead director.
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.